Department of Preclinical and Clinical Pharmacology "M. Aiazzi Mancini", Centre for Molecular Medicine (CIMMBA), University of Florence, Viale G. Pieraccini 6, 50139, Florence, Italy,
Intern Emerg Med. 2013 Oct;8(7):591-4. doi: 10.1007/s11739-011-0658-8. Epub 2011 Jul 9.
Pain treatment in Italy is far from being optimal. In order to improve this situation, the reporting of a complete assessment of pain in the clinical record became compulsory by law. Pain-related cancer protocols (143) were selected from the National Monitoring Centre of Clinical Trials Database and reviewed. Our data indicate that pain management is not being reported as it should be: treatment has been taken into account in only 36.4% of the protocols, and assessment in 37.1%. Furthermore, breakthrough cancer pain has never been reported. The main aim of cancer therapy is obviously control the disease, however Ethics Committees should pay close attention to pain therapy when evaluating clinical protocols.
意大利的疼痛治疗远非理想。为了改善这种情况,法律规定在临床记录中完整报告疼痛评估成为强制性要求。从国家临床试验监测中心数据库中选择了与疼痛相关的癌症方案(143 个)并进行了审查。我们的数据表明,疼痛管理并未得到应有的报告:只有 36.4%的方案考虑了治疗,37.1%的方案考虑了评估。此外,从未报告过突破性癌症疼痛。癌症治疗的主要目的显然是控制疾病,但是伦理委员会在评估临床方案时应密切关注疼痛治疗。